(CercleFinance.com) – Medincell indicates that it has received an additional grant of up to six million dollars over three years from the global health agency Unitaid to finance the phase 1 clinical study of the long-acting injectable treatment mdc -STM.
‘If it proves to be safe, effective and well tolerated, it could have a significant impact on the transmission of malaria in vulnerable populations residing in the most affected areas’, highlights the biopharmaceutical company.
Malaria remains endemic in 85 countries representing 50% of the world’s population. According to WHO estimates, 249 million people will have been infected worldwide in 2022, 94% of them in Africa, leading to 580,000 deaths in this region.
Copyright © 2024 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends using the buttons below.
